Compare OPHC & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | OPHC | ENGN |
|---|---|---|
| Founded | 2000 | 1999 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.1M | 117.2M |
| IPO Year | 2012 | 2023 |
| Metric | OPHC | ENGN |
|---|---|---|
| Price | $9.11 | $1.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $10.92 | $3.29 |
| AVG Volume (30 Days) | 57.3K | ★ 822.7K |
| Earning Date | 11-13-2026 | 12-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 56.85 |
| EPS | ★ 0.48 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.92 | $1.40 |
| 52 Week High | $10.68 | $12.25 |
| Indicator | OPHC | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 54.60 | 33.12 |
| Support Level | $8.48 | $1.40 |
| Resistance Level | $9.26 | $1.95 |
| Average True Range (ATR) | 0.38 | 0.09 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 67.16 | 3.35 |
OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides community banking services to individuals and corporate customers. The services provided by the bank include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal accounts, borrowings, repayment of loans, money market deposit accounts, debit cards, automated teller machines, and other bank related services.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.